Japanese researchers at Kyoto University Hospital and the Medical Research Institute Kitano Hospital in Osaka discovered and developed a groundbreaking tooth-regrowth drug called TRG035 through its spin-off company, Toregem BioPharma. Following successful safety studies in adults, the team cleared regulatory review in August 2026 to prepare Phase IIa trials in children, backed by Orphan Drug designation from Japan’s health ministry.
Scientifically, the treatment relies on the discovery that humans actually retain dormant "third-set" tooth buds beneath their gums. Normally, a protein called USAG-1 acts like a biological brake, suppressing bone morphogenetic protein (BMP) and Wnt signaling so these extra teeth never grow. After proving in mice and beagle dogs that blocking USAG-1 restores missing teeth, researchers created TRG035, a targeted monoclonal antibody that neutralizes this protein and awakens those hidden tooth germs to develop naturally.
Scientifically, the treatment relies on the discovery that humans actually retain dormant "third-set" tooth buds beneath their gums. Normally, a protein called USAG-1 acts like a biological brake, suppressing bone morphogenetic protein (BMP) and Wnt signaling so these extra teeth never grow. After proving in mice and beagle dogs that blocking USAG-1 restores missing teeth, researchers created TRG035, a targeted monoclonal antibody that neutralizes this protein and awakens those hidden tooth germs to develop naturally.
35 Zobrazení